Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, R&D

We take our company's mission seriously: to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

At Bristol-Myers Squibb, we’re on the leading edge of science and technology to discover and develop new medicines. We measure our success by the difference we can make in the lives of patients, offering them new treatment options and, more importantly, new hope.

Since late 2002, our R&D team has helped to bring to market 13 key medicines to treat cancer, serious mental illness, HIV/AIDS, hepatitis B, rheumatoid arthritis, cardiovascular disease, organ transplant and diabetes. Four of these medicines are biologics. In the fight against serious disease, biologics are playing an increasingly prominent role. More than one-third of our compounds in development are biologics.

Our pipeline continues to deliver. In 2011, 14 new compounds entered preclinical development and four transitioned to mid-stage clinical testing. In addition, we received approvals for three new medicines – an impressive number for a single year.

Our vision as a BioPharma leader is to combine the best elements of a traditional pharmaceutical company and those of a leading-edge biotech company by focusing on innovation, selective integration and continuous improvement.

Our R&D strategy is to pursue significant areas of unmet medical need by leveraging our legacy in discovering and developing high-potency small molecules as well as our growing experience and expertise in highly targeted biologics.

Building on the past, accelerating to the future. It’s all part of being BioPharma.